IL13RA2 and glioblastoma: In three patients with recurrent GBM, the feasibility of repetitive intracranial administration of first-generation IL13Rα2-specific CD8+ CAR T cells was demonstrated and transient anti-tumor activity for some patients was reported in the absence of serious adverse events, such as occlusion, malfunction, or infection [30].